spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  VIBATIV 

 HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Nov 2018
Cumberland Pharmaceuticals To Acquire VIBATIV(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals
 HSMN NewsFeed - 29 Jan 2018
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2017
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Nov 2017
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 20 Jul 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2016
Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2013
Clinigen Group plc Acquires Oncology Support Therapy Cardioxane(R) from a World-Leading Pharmaceutical Company
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.